Preemptively treating patients most at risk of progression to myeloma

What does the Association of European Cancer Leagues (ECL) do?

Biomarkers of sensitivity and resistance

Editor's ESMO 2016 roundup

Abiraterone in patients with recurrent epithelial ovarian cancer

Fatigue in men with castration resistant prostate cancer treated with enzalutamide

PDL-1 assay concordance

First evidence of significant clinical activity of PD1 inhibition in metastatic prostate cancer

CDK4/6 inhibitors for metastatic breast cancer

Who should receive combination therapy for ER positive breast cancer?

Positive lessons of negative trials

Drug repurposing of propranolol